Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis

References

• World Health Organization International Agency for Research on Cancer. GLOBOCAN 2012: estimated Cancer incidence, mortality and prevalence worldwide 2012 [cited 2017 Mar 23]; Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
   Google Scholar
• World Health Organization. Breast cancer: prevention and control. World Health Organization; 2017. [cited 2017 Mar 23]; Available from: https://www.who.int/cancer/detection/breastcancer/en/
   Google Scholar
• Coleman MP, Quaresma M, Berrino F, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol. 2008;9(8):730–756.
   PubMed Web of Science ®Google Scholar
• Burstein H. The distinctive nature of HER2-positive breast cancers. N Engl J Med. 2005 Oct 20;353(16):1652–1654.
   PubMed Web of Science ®Google Scholar
• Gajria D, Chandarlapaty S. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther. 2011;11(2):263–275.
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/College of American pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013.
   PubMed Web of Science ®Google Scholar
• Pathmanathan N, Geng JS, Li W, et al. Human epidermal growth factor receptor 2 status of breast cancer patients in Asia: results from a large, multicountry study. Asia Pac J Clin Oncol. 2016;12:369–379.
   PubMed Web of Science ®Google Scholar
• Giordano SH, Temin S, Chandarlapaty S, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2–positive breast cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018 Sep 10;36(26):2736–2740.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Guidelines version 2.2017. Breast Cancer; 2017; Pennsylvania, PA: National Comprehensive Cancer Network, Plymouth Meeting.
   Google Scholar
• Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v8–V30.
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–1684.
   PubMed Web of Science ®Google Scholar
• Slamon D, Eiermann W, Robert N, et al., Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 study. San Antonio Breast Cancer Symposium. 353(16):1652–1654, 2009.
   Google Scholar
• Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369(9555):29–36.
   PubMed Web of Science ®Google Scholar
• Bria E, Cuppone F, Fornier M, et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat. 2008;109(2):231–239.
   PubMed Web of Science ®Google Scholar
• Viani GA, Alfonso SL, Stefano EJ, et al. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer. 2007;7:153.
   PubMed Web of Science ®Google Scholar
• Dahabreh IJ, Linardou H, Siannis F, et al. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist. 2008;13(6):620–630.
   PubMed Web of Science ®Google Scholar
• Ward S, Pilgrim H, Hind D. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal. Health Technol Assess. 2009;13(Suppl. 1.).
   PubMedGoogle Scholar
• Yin W, Jiang Y, Shen Z, et al. Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials. PLoS ONE. 2011;6(6):e21030.
   PubMed Web of Science ®Google Scholar
• O’Sullivan CC, Bradburry I, Campbell C, et al. Efficacy of adjuvant trastuzumab for patients with human epidermal growth factor receptor 2–positive early breast cancer and tumors ≤ 2 cm: a meta-analysis of the randomized trastuzumab trials. J Clin Oncol. 2015 20;33(24):2600–2608.
   PubMed Web of Science ®Google Scholar
• Long HD, Lin YE, Zhang JJ, et al. Risk of congestive heart failure in early breast cancer patients undergoing adjuvant treatmentwith trastuzumab: a meta-analysis. Oncologist. 2016;21(5):547–554.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. Oncologist. 2006;11(8):857–867.
   PubMed Web of Science ®Google Scholar
• Madarnas Y, Trudeau M, Franek JA, et al. Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu overexpressing breast cancer: A systematic review. Cancer Treat Rev. 2008;34(6):539–557.
   PubMed Web of Science ®Google Scholar
• Mates M, Fletcher GG, Freedman OC, et al. Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 cancer care Ontario systemic therapy guideline. Curr Oncol. 2015;22(Suppl1):S114–S22.
   PubMedGoogle Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7).
   Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
   PubMed Web of Science ®Google Scholar
• Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2014. [cited 2017 Jul 1]; Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
   Google Scholar
• Towse A. Net clinical benefit: the art and science of jointly estimating benefits and risks of medical treatment. Value Health. 2010 Jun;13(Suppl 1):S30–S32.
   PubMedGoogle Scholar
• Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;369(9555):29–36.
   Google Scholar
• Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2–positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014;23(31):7811–7819.
   Google Scholar
• Romond EH, Jeong JH, Rastogi P, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2–positive breast cancer. J Clin Oncol. 2012;30(31):3792–3799.
   PubMed Web of Science ®Google Scholar
• Advani PP, Ballman KV, Dockter TJ, et al. Long term cardiac safety analysis of NCCTG N9831 (Alliance) adjuvant trastuzumab trial. J Clin Oncol. 2016;23(31):7811–7819.
   Google Scholar
• Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273–1283.
   PubMed Web of Science ®Google Scholar
• Joensuu H, Bono P, Kataja V, et al. Fluorouacil, epirubicin and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial. J Clin Oncol. 2009;27(34):5685–5692.
   PubMed Web of Science ®Google Scholar
• Spielmann M, Roche H, Delozier T, et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol. 2009;27(36):6129–6134.
   PubMed Web of Science ®Google Scholar
• Joensuu H, Kellokumpu-Lehtinen P, Huovinen R, et al. Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the finland capecitabine trial (FinXX). Acta Oncol. 2014;53(2):186–194.
   PubMed Web of Science ®Google Scholar